| Document |
Document Title |
|
WO/2024/085261A1 |
Provided are: a novel microparticle that includes miRNA for controlling the production of nitric oxide and that is an agent for promoting the production of nitric oxide, said microparticle being capable of controlling the expression of a...
|
|
WO/2023/229356A3 |
The present invention relates to a composition for preventing, alleviating or treating menopausal symptoms in women, containing, as an active ingredient, a mixture of fermented product of soybeans and lettuce. In the fermented product of...
|
|
WO/2024/082230A1 |
The present invention provides a use of deslorelin acetate in preparation of a drug for adjusting a sexual cycle of an animal. The animal is a rat, and the drug is an injection, preferably administered by subcutaneous injection. By using...
|
|
WO/2024/080482A1 |
The present invention relates to a composition for endometrial regeneration containing a uterus derived decellularized extracellular matrix (UdECM) and a manufacturing method therefor. Characterized by containing uterus derived decellula...
|
|
WO/2024/079758A1 |
The present invention discloses a pharmaceutical composition useful for enhancing sexual peak performance. The present invention relates to a synergistic herbal composition comprising Sodium succinate derived from Panax notoginseng along...
|
|
WO/2024/078488A1 |
Disclosed in the present invention are a thiochroman derivative and a preparation method therefor and a use thereof. The structure of the thiochroman derivative is as shown in general formula (I), and the definition of each substituent i...
|
|
WO/2024/079757A1 |
Disclosed herein is a herbal composition comprising Euphorbia royleana succinate and suitable pharmaceutical excipients. The invention also disclosed herein is process for preparation of said herbal composition.
|
|
WO/2024/079251A1 |
The present invention relates to the field of food supplementation, in particular to the field of nutraceuticals, more in particular to the use of a composition comprising oleuropein. More specifically, the present invention relates to t...
|
|
WO/2024/022079A9 |
A use of a human mesenchymal stem cell sheet in the preparation of a drug for treating uterine scars, and a use of a human mesenchymal stem cell sheet in the preparation of a composition for treating a uterine scar in a subject. The huma...
|
|
WO/2024/074105A1 |
The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-4, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell contain...
|
|
WO/2024/076995A1 |
Embodiments of the present invention provide a pharmaceutical intervention in the neonatal pig that inhibits and delays development and activation of the HPG axis, growth of the boar testis and inhibits testicular production of testoster...
|
|
WO/2024/076967A1 |
The present invention provides compositions and methods for reducing the level and/or activity of a TET protein, for treating or preventing a disease and disorder associated with an increased level and/or activity of a TET protein, for r...
|
|
WO/2024/074102A1 |
The present invention pertains to the field of biopharmaceuticals and provides a keratin YK93-6, a nucleic acid molecule encoding same, an expression vector comprising the nucleic acid molecule, a host cell that contains the expression v...
|
|
WO/2024/074107A1 |
The present invention belongs to the field of biopharmaceuticals. Provided are a keratin YK93-2, a nucleic acid molecule encoding the same, an expression vector comprising the nucleic acid molecule, a host cell comprising the expression ...
|
|
WO/2024/074110A1 |
The present invention relates to the field of biological pharmacy, provides keratin YK93-5, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or...
|
|
WO/2024/074104A1 |
The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-8, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell contain...
|
|
WO/2024/075050A1 |
The present application relates to a fusion protein including a follicle stimulating hormone and an antigen-binding fragment to serum albumin and a use thereof. Accordingly, a recombinant fusion protein, which includes an antigen-binding...
|
|
WO/2024/071039A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2024/068563A1 |
The present invention relates to an extract of Hericium erinaceus, or the composition comprising same, preferably obtained from the carpophore of said fungus, as well as the method for obtaining said extract by infusion and percolation. ...
|
|
WO/2024/072421A1 |
Disclosed herein are oral formulations for treating, preventing, or ameliorating symptoms associated with bacterial vaginosis or yeast infections. The oral formulations disclosed herein comprise a probiotic composition and a supplement c...
|
|
WO/2024/066596A1 |
Provided are a rehmannia and lycium root bark decoction water extract solution, a rehmannia and lycium root bark decoction water extract paste, a rehmannia and lycium root bark decoction preparation and a preparation method therefor, and...
|
|
WO/2024/067535A1 |
Provided are a small peptide and a use thereof in mucosal repair. The small peptide is selected from a basic small peptide having a sequence as shown in SEQ ID NO. 1 or SEQ ID NO. 2 or a lead small peptide containing the basic small pept...
|
|
WO/2024/067330A1 |
Provided is use of a pentacyclic triterpenoid compound in preparing a medicament for preventing and/or treating sarcoidosis. The pentacyclic triterpenoid compound has the advantages of causing small liver and kidney damage, being safe to...
|
|
WO/2024/072288A1 |
The present invention is directed to processes for obtaining phrgamalin derivatives e.g. of formula la from Entandrophragma caudatum seed extracts,formula (1a) and producing therapeutically active limonoids and limonoid-type compounds su...
|
|
WO/2024/067783A1 |
Provided are a compound represented by formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and use of the compound as an androgen receptor (AR) inhibitor.
|
|
WO/2024/062360A1 |
A compound of formula (I) having the structure: or a pharmaceutically acceptable salt thereof as SIK inhibitor, wherein A1 and A2 are independently O or S; X is selected from CH2, CD2, NR3, O, and S, where R3 is selected from hydrogen, C...
|
|
WO/2024/060911A1 |
Disclosed are a benzoisothiazole compound, and a pharmaceutical composition and use thereof. The present invention belongs to the technical field of medicines, and particularly relates to a novel structure 2H-benzotriazole-substituted be...
|
|
WO/2024/060912A1 |
The present invention provides a 2H-benzotriazole derivative, a preparation method therefor, and a pharmaceutical composition containing same, belongs to the technical field of medicines, and particularly relates to a 2H-benzotriazole de...
|
|
WO/2024/062419A1 |
Chinese herbal formulations comprising at least one herb or a component thereof from three or more different classes of Chinese herbs selected from Blood tonifying, Blood moderators, Blood heat coolers, body heat coolers and Yang tonic a...
|
|
WO/2024/060948A1 |
The present invention relates to a T cell receptor (TCR) specifically binding to a human papillomavirus E7, a nucleic acid encoding the TCR, an engineered cell comprising same, and a method for preparing the engineered cell. The present ...
|
|
WO/2024/052570A1 |
The present invention relates to the use of carbon monoxide for the preservation of gametes. The present invention provides for means and methods for the preservation of gametes. An inventive method comprises the steps of a) providing ga...
|
|
WO/2024/050861A1 |
Use of RUNX2 as a marker and a treatment target in screening for and preparing a medicament for combating malignant phyllodes tumors of the breast, and use of the RUNX2 inhibitor CAD522 in preparing a medicament for combating malignant p...
|
|
WO/2024/050596A1 |
The present disclosure generally relates to methods of determining the probability of live birth and to methods of, and compositions for, increasing the probability of live birth. The methods disclosed include an analysis of the level an...
|
|
WO/2024/052864A1 |
The invention relates to substantially complete vaginal microbiota preparations for treating infertility and therapeutic methods to do so.
|
|
WO/2024/054524A1 |
Compositions and methods for treating one or more symptoms associated with vaginal atrophy or discomfort are disclosed. The compositions include an effective amount of one or more of the active agents selected from pectin (P), hyaluronic...
|
|
WO/2024/047229A1 |
There is provided herein a compound of formula (I), as defined herein, or a pharmaceutically acceptable salt thereof, and formulations comprising the same for use in the treatment or prophylaxis of endometriosis.
|
|
WO/2024/046168A1 |
Provided are a Lactobacillus brevis strain and anti-cervical cancer use thereof. The provided Lactobacillus brevis is specifically (Lactobacillus brevis) YNH, which is deposited under CGMCC No. 24368 at the China General Microbiological ...
|
|
WO/2024/048795A1 |
The present invention provides: a conception chance-improving composition for normalization of EGF concentration profile and conception chance improvement for a ruminant; and a method for improving ruminant conception chance using said c...
|
|
WO/2024/049450A1 |
The embodiments disclose a method including determining populations of Lactobacilli bacterial species associated with a predetermined health level for genital microbiome conditions to screen ointment preparations and ingredients for thei...
|
|
WO/2024/046292A1 |
The present invention relates to the technical field of medicines, and in particular, to a mesylate crystalline form of a TAM family kinase and/or CSF1R kinase and/or NTRK inhibitor shown in a formula (I), a preparation method therefor a...
|
|
WO/2023/152682A9 |
Described are methods of providing contraception with increased likelihood of scheduled bleeding in a woman having a BMI < 30.0 kg/m2 and methods of providing contraception with reduced likelihood of scheduled bleeding in a woman having ...
|
|
WO/2024/042494A1 |
The inventive compounds are small molecule therapeutics that are potent inhibitors of USP7 activity. The invention also provides pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or pr...
|
|
WO/2024/038162A1 |
Disclosed herein is akhdardiol or a pharmaceutically acceptable salt thereof for use in a method of treating fungal infections in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effect...
|
|
WO/2024/035964A1 |
Featured are compositions and methods for an ovarian implant comprising ovarian support cells. In particular, the disclosure features methods of culturing ovarian support cells for the purpose of implantation into a subject in need there...
|
|
WO/2024/032452A1 |
Provided is a Lactiplantibacillus plantarum 1-D1 strain and a use thereof. The strain features genetic stability, no pathogenic/virulent genes, good safety and strong antimicrobial ability to pathogenic microorganisms, and can reduce vag...
|
|
WO/2024/028794A1 |
The disclosure provides for methods and compositions that target the interaction of αV/β1 integrin and monomeric MPO in ovarian cancer and other hyperproliferative disorders. Accordingly, aspects of the disclosure relate to a method fo...
|
|
WO/2024/030116A1 |
The invention relates to a drug delivery system for contraception including a steroidal estrogenic compound, a steroidal progestogenic compound or a combination thereof for the purposes of contraception in a subject, and provides for an ...
|
|
WO/2024/028764A1 |
The present invention relates to the Lacticaseibacillus rhamnosus DSM 33960 bacterial strain, and its use in a method for the prevention and treatment of conditions of dysbiosis of the female urogenital tract, preferably vaginal dysbiosis
|
|
WO/2024/029608A1 |
Provided is a therapeutic agent that is effective for the treatment of ovarian clear cell carcinoma. The therapeutic agent for ovarian clear cell carcinoma contains a proteasome inhibitor as an active ingredient. Moreover, said proteasom...
|
|
WO/2024/027673A1 |
Provided is the use of a nocardia rubra cell wall skeleton in the preparation of a drug. The drug is used for preventing or treating chronic cervicitis accompanied by high-risk HPV infection in a subject.
|
